* Corbus Pharmaceuticals Holdings Inc CRBP.OQ reported a
quarterly adjusted loss of $1.15 per share for the quarter
ended September 30, higher than the same quarter last year, when
the company reported EPS of $-2.05. The mean expectation of
eight analysts for the quarter was for a loss of 95 cents per
share. Wall Street expected results to range from $-1.14 to -74
cents per share.
* Reported revenue was zero; analysts expected zero.
* Corbus Pharmaceuticals Holdings Inc's reported EPS for the
quarter was a loss of $1.15.
* The company reported a quarterly loss of $13.78 million.
* Corbus Pharmaceuticals Holdings Inc shares had fallen
by 8.3%
this quarter and gained 213.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 2.4%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Corbus
Pharmaceuticals Holdings Inc is $62.50
This summary was machine generated from LSEG data November 7 at
08:43 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.95 -1.15 Missed
Jun. 30 2024 -1.19 -0.90 Beat
Mar. 31 2024 -1.09 -0.83 Beat
Dec. 31 2023 -2.36 -1.81 Beat